Skip to content
2000
Volume 13, Issue 5
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

Hesperetin is a compound from citrus fruit that has previously been found to exert anticancer activity through a variety of mechanisms. However, the application of hesperetin to cancer therapy has been hampered by its hydrophobicity, necessitating the use of toxic solubilizing agents. Here, we have developed the first liposome-based delivery system for hesperetin. Liposomes were fabricated using the thin-layer evaporation technique and physical and pharmacological parameters were measured. The liposomes remained stable for prolonged periods of time in serum and under storage conditions, and displayed anticancer efficacy in both H441 lung cancer cells and MDA-MB-231 breast cancer cells. Furthermore, the anticancer activity was not impaired in cells expressing the multidrug resistance protein 1 (MDR-1). In conclusion, the encapsulation of hesperetin in liposomes does not interfere with therapeutic efficacy and provides a biocompatible alternative to toxic solubilizing agents, thereby enabling future clinical use of this compound for cancer therapy.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/1567201812666151027142412
2016-08-01
2025-09-03
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/1567201812666151027142412
Loading

  • Article Type:
    Research Article
Keyword(s): Breast cancer; Drug delivery; Flavanone; Lung cancer; MDR-1; Natural products
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test